前の章|次の章

甲状腺関連眼症治療のためのCARベース治療における新たな展望の探求

  • role： First author第一作者
  • Affiliation：

    Department of Endocrinology, the Second Affiliated Hospital of Naval Medical University, Shanghai 20003, China

Xin-Yu Zhu1,  
  • Affiliation：

    Department of Endocrinology, the Second Affiliated Hospital of Naval Medical University, Shanghai 20003, China

Wei-Yi Zhou1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Endocrinology, the Second Affiliated Hospital of Naval Medical University, Shanghai 20003, China

  • Email：dr.lituo@smmu.edu.cn
  • Introduction：* Tuo Li dr.lituo@smmu.edu.cn
Tuo Li1*

サマリー

キーワード

Thyroid-associated ophthalmopathy (TAO);Graves’ ophthalmopathy (GO);Chimeric antigen receptor(CAR)-based therapy

References

  1. 1..
    Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-38.
  2. 2..
    Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43-67.
  3. 3..
    Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):62.
  4. 4..
    Chang HH, Wu SB, Tsai CC. A review of pathophysiology and thera-peutic strategies targeting TGF-β in Graves’ ophthalmopathy. Cells.2024;13(17):1493.
  5. 5..
    Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890-904.e9.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website